ATE442843T1 - Verwendung von c-terminal modifizierter oxamyl dipeptide als inhibitoren von der ice/ced-3 familie von cystein proteasen - Google Patents

Verwendung von c-terminal modifizierter oxamyl dipeptide als inhibitoren von der ice/ced-3 familie von cystein proteasen

Info

Publication number: ATE442843T1
Authority: AT; Austria
Prior art keywords: ced; inhibitors; ice; family; terminal modified
Prior art date: 1998-07-02

Application number

AT06125650T

Other languages

English (en)

Inventor

Donald Karanewsky

Robert Ternansky

Original Assignee

Idun Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-02

Filing date

1999-07-01

Publication date

2009-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26784233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE442843(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-07-01 Application filed by Idun Pharmaceuticals Inc filed Critical Idun Pharmaceuticals Inc

2009-10-15 Application granted granted Critical

2009-10-15 Publication of ATE442843T1 publication Critical patent/ATE442843T1/de

Links

108010016626 Dipeptides Proteins 0.000 title 1
102000035195 Peptidases Human genes 0.000 title 1
108091005804 Peptidases Proteins 0.000 title 1
239000004365 Protease Substances 0.000 title 1
101150055276 ced-3 gene Proteins 0.000 title 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
KZAUOCCYDRDERY-UITAMQMPSA-N methyl (1z)-2-(dimethylamino)-n-(methylcarbamoyloxy)-2-oxoethanimidothioate Chemical group CNC(=O)O\N=C(/SC)C(=O)N(C)C KZAUOCCYDRDERY-UITAMQMPSA-N 0.000 title 1
208000035473 Communicable disease Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000004968 inflammatory condition Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1
230000035899 viability Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3258—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3264—Esters with hydroxyalkyl compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Biophysics (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT06125650T 1998-07-02 1999-07-01 Verwendung von c-terminal modifizierter oxamyl dipeptide als inhibitoren von der ice/ced-3 familie von cystein proteasen ATE442843T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9168998P	1998-07-02	1998-07-02
US09/177,549 US6197750B1 (en)	1998-07-02	1998-10-22	C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases

Publications (1)

Publication Number	Publication Date
ATE442843T1 true ATE442843T1 (de)	2009-10-15

Family

ID=26784233

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT06125650T ATE442843T1 (de)	1998-07-02	1999-07-01	Verwendung von c-terminal modifizierter oxamyl dipeptide als inhibitoren von der ice/ced-3 familie von cystein proteasen
AT99932211T ATE348096T1 (de)	1998-07-02	1999-07-01	C-terminal modifizierte oxamyl dipeptide als inhibitorse von der ice/ced-3 familie von cystein proteasen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT99932211T ATE348096T1 (de)	1998-07-02	1999-07-01	C-terminal modifizierte oxamyl dipeptide als inhibitorse von der ice/ced-3 familie von cystein proteasen

Country Status (22)

Country	Link
US (1)	US6197750B1 (de)
EP (2)	EP1754475B1 (de)
JP (1)	JP3815968B2 (de)
KR (1)	KR100804432B1 (de)
CN (1)	CN1159289C (de)
AT (2)	ATE442843T1 (de)
AU (1)	AU752339B2 (de)
BR (1)	BR9911675A (de)
CA (1)	CA2336474C (de)
CY (1)	CY1108088T1 (de)
DE (2)	DE69941440D1 (de)
DK (2)	DK1091930T3 (de)
ES (2)	ES2330663T3 (de)
HU (1)	HUP0102898A3 (de)
ID (1)	ID28263A (de)
IL (1)	IL140554A0 (de)
MX (1)	MXPA00013014A (de)
NO (1)	NO20006544L (de)
NZ (1)	NZ509025A (de)
PL (1)	PL207578B1 (de)
PT (1)	PT1091930E (de)
WO (1)	WO2000001666A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1647279A3 (de) *	1996-09-12	2006-04-26	Idun Pharmaceuticals, Inc.	Hemmung der Apoptose unter Verwendung von Inhibitoren der Interleukin-1 Beta converting Enzym (ICE)/CED-3 Familie
US6184210B1 (en) *	1997-10-10	2001-02-06	Cytovia, Inc.	Dipeptide apoptosis inhibitors and the use thereof
PL204619B1 (pl) *	1998-03-19	2010-01-29	Vertex Pharma	Pochodna peptydowa, kompozycja farmaceutyczna zawierająca taką pochodną i zastosowanie pochodnej peptydowej
US6544951B2 (en)	1998-07-02	2003-04-08	Idun Pharmaceuticals, Inc.	C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US7053056B2 (en) *	1998-07-02	2006-05-30	Idun Pharmaceuticals, Inc.	C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
CA2369619A1 (en)	1999-04-09	2000-10-19	Cytovia, Inc.	Caspase inhibitors and the use thereof
US6495522B1 (en)	1999-08-27	2002-12-17	Cytovia, Inc.	Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
KR20020058078A (ko)	1999-12-03	2002-07-12	우에노 도시오	옥사디아졸 유도체 및 그 유도체를 유효 성분으로 하는 약제
US6515173B1 (en)	2000-01-13	2003-02-04	Idun Pharmaceuticals, Inc.	Inhibitors of the ICE/ced-3 family of cysteine proteases
US6790989B2 (en) *	2000-01-13	2004-09-14	Idun Pharmaceuticals, Inc.	Inhibitors of the ICE/ced-3 family of cysteine proteases
US6867299B2 (en)	2000-02-24	2005-03-15	Hoffmann-La Roche Inc.	Oxamide IMPDH inhibitors
US6525024B1 (en)	2000-04-17	2003-02-25	Idun Pharmaceuticals, Inc.	Inhibitors of the ICE/ced-3 family of cysteine proteases
AU2001253633A1 (en) *	2000-04-17	2001-10-30	Idun Pharmaceuticals, Inc.	Inhibitors of the ice/ced-3 family of cysteine proteases
PE20011350A1 (es)	2000-05-19	2002-01-15	Vertex Pharma	PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US20030039661A1 (en) *	2001-03-02	2003-02-27	Teresa Aja	Methods, compositions and kits for preserving antigenicity
US7282512B2 (en)	2002-01-17	2007-10-16	Smithkline Beecham Corporation	Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
EP1485107A1 (de) *	2002-02-11	2004-12-15	Vertex Pharmaceuticals Incorporated	Phospholipide als caspase-hemmer-prodrugs
EP1499898A2 (de) *	2002-04-19	2005-01-26	Vertex Pharmaceuticals Incorporated	Regulierung von tnf-alpha
US6727241B2 (en) *	2002-06-12	2004-04-27	Chemocentryx	Anti-inflammatory compositions and methods of use
CA2500196A1 (en) *	2002-09-25	2004-04-08	University Of Rochester	Caspase inhibitors as anticancer agents
EP1583726A4 (de) *	2002-10-09	2009-06-10	Activx Biosciences Inc	Auf wirkung basierende sonden und verfahren zu deren herstellung und verwendung
PE20050159A1 (es) *	2003-05-27	2005-04-19	Vertex Pharma	Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
AU2003902704A0 (en) *	2003-05-29	2003-06-19	Crc For Waste Management And Pollution Control Limited Of Unsw	Process for producing a nanoscale zero-valent metal
SG146624A1 (en) *	2003-09-11	2008-10-30	Kemia Inc	Cytokine inhibitors
WO2005047906A1 (en) *	2003-11-10	2005-05-26	Vertex Pharmaceuticals Incorporated	Methods for monitoring il-18
AU2005223767B2 (en) *	2004-03-12	2011-12-01	Vertex Pharmaceuticals Incorporated	Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
CN1980658A (zh) *	2004-05-27	2007-06-13	沃泰克斯药物股份有限公司	治疗自身炎性疾病的ice抑制剂
WO2006057961A1 (en)	2004-11-24	2006-06-01	Vertex Pharmaceuticals Incorporated	3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
EP1904100A1 (de) *	2005-07-11	2008-04-02	Pfizer Limited	Neue kombination von anti-madcam-antikörper und antifibrotischem caspase-hemmer zur behandlung von leberfibrose
KR20080038369A (ko) *	2005-07-28	2008-05-06	버텍스 파마슈티칼스 인코포레이티드	카스파제 억제제 프로드럭
CN103951583B (zh) *	2006-12-06	2016-01-06	科内图斯医药公司	一种抑制剂的结晶形式
JP6006908B2 (ja)	2010-11-05	2016-10-12	ブランダイスユニバーシティＢｒａｎｄｅｉｓＵｎｉｖｅｒｓｉｔｙ	Ｉｃｅ阻害化合物およびその使用
US9956260B1 (en)	2011-07-22	2018-05-01	The J. David Gladstone Institutes	Treatment of HIV-1 infection and AIDS
EP4218829A3 (de)	2013-03-15	2023-08-16	The Board of Trustees of the Leland Stanford Junior University	Aktivitätsbasierte sondenverbindungen, zusammensetzungen und verfahren zur verwendung
MX2016014731A (es)	2014-05-12	2017-05-04	Conatus Pharmaceuticals Inc	Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
EP3265440A1 (de)	2015-03-06	2018-01-10	Concert Pharmaceuticals Inc.	Deuteriertes emricasan
WO2017079566A1 (en)	2015-11-05	2017-05-11	Conatus Pharmaceuticals, Inc.	Caspase inhibitors for use in the treatment of liver cancer
KR20180101418A (ko)	2015-12-31	2018-09-12	코나터스 파마슈티칼스, 인크.	간 질환의 치료에서의 카스파제 억제제의 사용 방법
CN108884045B (zh) *	2016-05-11	2020-12-04	正大天晴药业集团股份有限公司	Caspase抑制剂及其药物组合物、用途和治疗方法
MX2019003889A (es)	2016-10-05	2019-08-12	Novartis Ag	Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
CN116217656B (zh)	2016-12-23	2026-05-08	里兰斯坦福初级大学理事会	基于活性的探针化合物、组合物及其使用方法
CN113354708B (zh) *	2017-01-23	2024-05-14	正大天晴药业集团股份有限公司	作为Caspase抑制剂的联环化合物
AU2019233195A1 (en)	2018-03-13	2020-09-24	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	A crystal of a caspase inhibitor
US11447497B2 (en)	2018-06-29	2022-09-20	Histogen, Inc.	(S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
WO2022123062A1 (en)	2020-12-11	2022-06-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients
IL315185A (en) *	2022-02-25	2024-10-01	Carmel Haifa Univ Economic Corporation Ltd	Apoptosis related protein in the tgf-beta signaling pathway (arts) mimetic compounds, compositions, methods and uses thereof in induction of apoptosis
CN119529128B (zh) *	2024-11-21	2026-04-17	中国科学院昆明植物研究所	具有抗白血病活性的当归多糖aps-1 ii 13糖和子结构9糖的制备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6204261B1 (en) *	1995-12-20	2001-03-20	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β Converting enzyme inhibitors
EP0618223A3 (de)	1993-03-08	1996-06-12	Sandoz Ltd	Peptide, die Freisetzung vom Interleukin 1-Bêta, nützlich als entzündungshemmende Wirkstoffe.
CA2122227A1 (en)	1993-04-29	1994-10-30	Roland E. Dolle	Peptide analogs as irreversible interleukin-1.beta. protease inhibitors
US5869519A (en) *	1996-12-16	1999-02-09	Idun Pharmaceuticals, Inc.	C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5968927A (en) *	1996-09-20	1999-10-19	Idun Pharmaceuticals, Inc.	Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US5877197A (en) *	1996-12-16	1999-03-02	Karanewsky; Donald S.	C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases

1998
- 1998-10-22 US US09/177,549 patent/US6197750B1/en not_active Expired - Lifetime
1999
- 1999-07-01 NZ NZ509025A patent/NZ509025A/en not_active Application Discontinuation
- 1999-07-01 EP EP06125650A patent/EP1754475B1/de not_active Expired - Lifetime
- 1999-07-01 CN CNB998100196A patent/CN1159289C/zh not_active Expired - Lifetime
- 1999-07-01 AT AT06125650T patent/ATE442843T1/de not_active IP Right Cessation
- 1999-07-01 JP JP2000558071A patent/JP3815968B2/ja not_active Expired - Lifetime
- 1999-07-01 KR KR1020007015074A patent/KR100804432B1/ko not_active Expired - Lifetime
- 1999-07-01 HU HU0102898A patent/HUP0102898A3/hu unknown
- 1999-07-01 PL PL345350A patent/PL207578B1/pl not_active IP Right Cessation
- 1999-07-01 DK DK99932211T patent/DK1091930T3/da active
- 1999-07-01 MX MXPA00013014A patent/MXPA00013014A/es active IP Right Grant
- 1999-07-01 ID IDW20010254A patent/ID28263A/id unknown
- 1999-07-01 IL IL14055499A patent/IL140554A0/xx not_active IP Right Cessation
- 1999-07-01 EP EP99932211A patent/EP1091930B1/de not_active Expired - Lifetime
- 1999-07-01 WO PCT/US1999/015074 patent/WO2000001666A1/en not_active Ceased
- 1999-07-01 DE DE69941440T patent/DE69941440D1/de not_active Expired - Lifetime
- 1999-07-01 AT AT99932211T patent/ATE348096T1/de active
- 1999-07-01 DE DE69934405T patent/DE69934405T2/de not_active Expired - Lifetime
- 1999-07-01 AU AU48569/99A patent/AU752339B2/en not_active Expired
- 1999-07-01 DK DK06125650T patent/DK1754475T3/da active
- 1999-07-01 CA CA002336474A patent/CA2336474C/en not_active Expired - Lifetime
- 1999-07-01 ES ES06125650T patent/ES2330663T3/es not_active Expired - Lifetime
- 1999-07-01 ES ES99932211T patent/ES2276520T3/es not_active Expired - Lifetime
- 1999-07-01 BR BR9911675-8A patent/BR9911675A/pt not_active IP Right Cessation
- 1999-07-01 PT PT99932211T patent/PT1091930E/pt unknown
2000
- 2000-12-21 NO NO20006544A patent/NO20006544L/no unknown
2007
- 2007-02-22 CY CY20071100251T patent/CY1108088T1/el unknown

Also Published As

Publication number	Publication date
HUP0102898A2 (hu)	2002-01-28
KR100804432B1 (ko)	2008-02-20
CN1159289C (zh)	2004-07-28
AU752339B2 (en)	2002-09-19
CA2336474A1 (en)	2000-01-13
EP1091930B1 (de)	2006-12-13
DE69934405T2 (de)	2007-10-31
DK1754475T3 (da)	2009-11-09
ATE348096T1 (de)	2007-01-15
DE69934405D1 (de)	2007-01-25
IL140554A0 (en)	2002-02-10
US6197750B1 (en)	2001-03-06
ES2276520T3 (es)	2007-06-16
NO20006544L (no)	2001-02-28
ES2330663T3 (es)	2009-12-14
CN1313846A (zh)	2001-09-19
BR9911675A (pt)	2002-02-05
DK1091930T3 (da)	2007-04-02
CY1108088T1 (el)	2014-02-12
CA2336474C (en)	2008-04-29
WO2000001666A1 (en)	2000-01-13
PL345350A1 (en)	2001-12-17
NO20006544D0 (no)	2000-12-21
HUP0102898A3 (en)	2002-09-30
EP1754475B1 (de)	2009-09-16
JP3815968B2 (ja)	2006-08-30
MXPA00013014A (es)	2004-04-02
AU4856999A (en)	2000-01-24
EP1754475A1 (de)	2007-02-21
DE69941440D1 (de)	2009-10-29
PT1091930E (pt)	2007-02-28
KR20010083079A (ko)	2001-08-31
NZ509025A (en)	2003-05-30
JP2002519406A (ja)	2002-07-02
EP1091930A1 (de)	2001-04-18
ID28263A (id)	2001-05-10
PL207578B1 (pl)	2011-01-31
HK1036616A1 (en)	2002-01-11

Legal Events

Date	Code	Title	Description
2010-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69934405D1 (de)	2007-01-25	C-terminal modifizierte oxamyl dipeptide als inhibitorse von der ice/ced-3 familie von cystein proteasen
ATE193304T1 (de)	2000-06-15	Inhibitoren der menschlichen neutrophilenelastase
TR199901191T2 (xx)	1999-12-21	Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
MXPA02011466A (es)	2003-04-25	Derivados de fenilglicina..
ES2128283T1 (es)	1999-05-16	Profarmacos de inhibidores de trombina.
DE60104141D1 (de)	2004-08-05	Substituierte dipeptide zur förderung der sekretion von wachstumshormon
NO934218L (no)	1993-11-22	Inhibitorer av cathepsin g og elastase for forhindring av bindevevsned-brytning
BG104885A (en)	2001-05-31	Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
MXPA03006224A (es)	2004-10-15	Inhibidores de cruzipaina y otras proteasas de cisteina.
BR9711540A (pt)	2001-06-19	Inibidores de protease proteìnico estabilizados e variantes dos mesmos
FI970279A0 (fi)	1997-01-23	Orgaanisia yhdisteitä
AR021241A1 (es)	2002-07-03	Inhibidores de proteasas
ATE427653T1 (de)	2009-04-15	Stabilisierung der milch transgener tieren
DE60040348D1 (de)	2008-11-06	R verwendung des diphtheria-toxins
BR9808210A (pt)	2000-05-16	Befeniloxazolinas dissubstituìdas
DE60203726D1 (de)	2005-05-19	Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
DE60007991D1 (de)	2004-03-04	Verwendung des proteins uk 114 zur verhinderung der abstossung eines transplantierten organs
ATE340569T1 (de)	2006-10-15	Verwendung eines neuen mittels zur verhütung von infektionen
ATE238781T1 (de)	2003-05-15	Verwendung von katecholderivaten als proteinaseinhibitoren
ECSP993018A (es)	1999-11-29	Nuevos inhibidores de proteasas, particularmente inhibidores de cisteina y serina proteasas